Home›Stock Screener›Akums Drugs & Pharma›Financial Statements

Akums Drugs & Pharma Complete Financial Statements

9 Years of Data
2026 - 2015

In FY2026, Akums Drugs & Pharma (AKUMS) reported revenue ₹1,193 Cr, net profit ₹81 Cr and EPS ₹5.53, with a net profit margin of 6.8% and ROE of 2.4%. Full financial statements from FY2015 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Akums Drugs & Pharma share price chart.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 6.79% 2026 data
EBITDA Margin 15.51% 2026 data
Operating Margin 13.00% 2026 data
Return on Assets 1.49% 2026 data
Return on Equity 2.43% 2026 data

Balance Sheet Ratios

Current Ratio 3.49 2026 data
Equity Ratio 61.15% 2026 data
Asset Turnover 0.22 2026 data

AKUMS Revenue, Net Profit & EBITDA — Year-on-Year Growth

AKUMS YoY (Mar 2025 vs Mar 2026) — revenue +10.4%, net profit -46.0%, EBITDA +54.2%, expenses +4.8%. Examine AKUMS earnings report for recent quarterly revenue, profit and EPS trends.

Revenue Growth
+10.4%
Year-over-Year
Net Profit Growth
-46.0%
Year-over-Year
EBITDA Growth
+54.2%
Year-over-Year
Expense Growth
+4.8%
Year-over-Year
Assets Growth
+32.4%
Year-over-Year
Equity Growth
+8.7%
Year-over-Year
Operating Cash Flow Growth
+154.0%
Year-over-Year
Investing Cash Flow Growth
-69.7%
Year-over-Year
Financing Cash Flow Growth
-53.4%
Year-over-Year

AKUMS Income Statement — Revenue, EBITDA & Net Profit

Akums Drugs & Pharma revenue ₹1,193 Cr, EBITDA ₹185 Cr, net profit ₹81 Cr, EPS ₹5.53 (2026) — net profit margin 6.8%. Analyse Akums Drugs & Pharma shareholding analysis to track promoter, FII and institutional holdings.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Jun 2023 Dec 2023
Revenue 1,193 1,050 1,081 1,051 1,194 1,050 955 1,026 1,030 1,188 978 1,093
Expenses 1,008 923 962 895 1,031 912 941 891 889 1,057 1,095 989
EBITDA 185 127 120 156 163 138 14 135 141 131 -117 103
Operating Profit Margin % 13.00% 9.00% 9.00% 13.00% 11.00% 12.00% 0.00% 13.00% 12.00% 11.00% -13.00% 9.00%
Depreciation 40 38 40 37 40 35 34 34 45 30 30 32
Interest 24 23 5 23 24 12 12 13 5 14 12 12
Profit Before Tax 121 66 75 96 100 92 -33 88 91 87 -159 59
Tax 40 23 -75 31 32 25 7 26 25 54 29 -136
Net Profit 81 43 150 65 68 67 -40 61 66 33 -187 195
Earnings Per Share (₹) 5.53 2.66 9.64 4.15 4.33 4.37 -2.89 4.21 4.26 2.22 -13.16 13.21

AKUMS Balance Sheet — Assets, Liabilities & Shareholders' Equity

AKUMS total assets ₹5,447 Cr, total equity ₹3,331 Cr, total liabilities ₹ Cr (2026) — ROE 2.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 5,447 4,113 3,516 3,267 3,069 2,167 2,078
Current Assets 3,560 2,275 1,941 1,879 1,864 1,157 1,250
Fixed Assets 1,456 1,397 1,191 1,097 1,021 904 645
Capital Work in Progress 177 163 195 103 31 17 57
Investments 0 0 0 0 0 20 6
Other Assets 3,814 2,553 2,130 2,066 2,017 1,226 1,371
LIABILITIES
Total Liabilities
Current Liabilities 1,021 156 1,585 1,278 1,172 700 627
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 3,331 3,064 721 723 625 887 721
Share Capital 31 31 29 29 14 1 1
Reserves & Surplus 3,283 3,016 681 689 608 884 721

AKUMS Cash Flow Statement — Operating, Investing & Financing

Akums Drugs & Pharma operating cash flow ₹1,181 Cr, investing ₹-930 Cr, financing ₹34 Cr, net cash flow ₹285 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2016 March 2015
Operating Activities 1,181 465 498 177 32 131 28 89 72
Investing Activities -930 -548 -331 -305 -235 -109 -190 -123 -150
Financing Activities 34 73 -108 125 236 -92 233 37 66
Net Cash Flow 285 -10 59 -4 33 -70 71 4 -11